Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases

Clinical Immunology

Volumn 123, Issue 3, 2007, Pages 235-243

  Looney, R John ^a   Diamond, Betty ^b   Holers, V Michael ^a   Levesque, Marc C ^a   Moreland, Larry ^b   Nahm, Moon H ^b   St Clair, E William ^a  

^a Autoimmunity Centers of Excellence (ACE) Immunocompetency Committee   (United States)

^b Autoimmunity Centers of Excellence (ACE) Immunocompetency Committee   (United States)

Author keywords

Autoimmunity; Clinical trials; Guidelines; Immunization; Immunocompetency; Immunosuppression

Indexed keywords

ABATACEPT; ANTIGEN; ANTIMALARIAL AGENT; DIPHTHERIA TOXOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; DRUG USE; EVALUATION; GENOTYPE; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; INFECTION RATE; INNATE IMMUNITY; MEDICAL SOCIETY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; SHORT SURVEY; VIRUS INFECTION;

AUTOIMMUNE DISEASES; CLINICAL TRIALS; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; VIRUS DISEASES;

EID: 34249686582     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.01.001     Document Type: Short Survey

References (69)

1. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. (see comment). New England Journal of Medicine 338 (1998) 1741-1751
2. Thorley-Lawson D.A. EBV the prototypical human tumor virus-just how bad is it?. Journal of Allergy and Clinical Immunology 116 (2005) 251-261 (quiz 262)
3. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
4. Humar A., Michaels M., and Monitoring A.I.W.G.o.I.D. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. American Journal of Transplantation 6 (2006) 262-274
5. Westhoven R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., and Rahman M.U. The safety of infliximab, combined with background treatment, among patients with rheumatoid arthritis and various comorbidities. Arthritis and Rheumatism 54 (2006) 1075-1086
6. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (see comment). New England Journal of Medicine 343 (2000) 1594-1602
7. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., Martin Mola E., Pavelka K., Sany J., Settas L., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. (see comment). Lancet 363 (2004) 675-681
8. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Wasko M.C., Moreland L.W., Weaver A.L., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. (see comment). Arthritis and Rheumatism 46 (2002) 1443-1450
9. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. (see comment, erratum appears in Arthritis Rheum. 48 (3) (2003, Mar) 855). Arthritis and Rheumatism 48 (2003) 35-45
10. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., Sharp J., Perez J.L., and Spencer-Green G.T. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 54 (2006) 26-37
11. van de Putte L.B., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L., Schattenkirchner M., Emery P., Burmester G.R., Zeidler H., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases 62 (2003) 1168-1177
12. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., Fischkoff S.A., and Chartash E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism 50 (2004) 1400-1411
13. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). (see comment). Journal of Rheumatology 30 (2003) 2563-2571
14. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and Rheumatism 52 (2005) 3403-3412
15. Gluck T. Vaccinate your immunocompromised patients!. (comment). Rheumatology 45 (2006) 9-10
16. Austrian R., Douglas R.M., Schiffman G., Coetzee A.M., Koornhof H.J., Hayden-Smith S., and Reid R.D. Prevention of pneumococcal pneumonia by vaccination. Transactions of the Association of American Physicians 89 (1976) 184-194
17. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., and Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals: a randomized trial. (see comment). JAMA 281 (1999) 908-913
18. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., Bridges C.B., Advisory Committee on Immunization Practices, and C.f.D.C.a.P. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). (erratum appears in MMWR Morb Mortal Wkly Rep. 54 (30) (2005, Aug 5) 750, update of MMWR Recomm Rep. 2004 May 28;53(RR-6):1-40; PMID: 15163927). Morbidity and Mortality Weekly Report. Recommendations and Reports 54 (2005) 1-40
19. Stray-Pedersen A., Aaberge I.S., Fruh A., and Abrahamsen T.G. Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clinical and Experimental Immunology 140 (2005) 507-516
20. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., and Katz J.M. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. (see comment). Journal of Infectious Diseases 191 (2005) 1210-1215
21. Banzhoff A., Nacci P., and Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 (2003) 177-184
22. Romero-Steiner S., Frasch C.E., Carlone G., Fleck R.A., Goldblatt D., and Nahm M.H. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clinical and Vaccine Immunology: CVI 13 (2006) 165-169
23. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Journal of Clinical Investigation 103 (1999) 1243-1252
24. Bearden C.M., Agarwal A., Book B.K., Vieira C.A., Sidner R.A., Ochs H.D., Young M., and Pescovitz M.D. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. American Journal of Transplantation 5 (2005) 50-57
25. D. Albert, S. Khan, J. Stansberry, S. Kolasinski, D. Tsai, M. Kamoun, R. Eisenberg, A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. Abstract #1125. Arthritis and Rheum 50 (Supp): S446-S447, 2004.
26. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. (see comment). New England Journal of Medicine 352 (2005) 2598-2608
27. Callan M.F. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Current Opinion in Rheumatology 16 (2004) 399-405
28. Gross A.J., Hochberg D., Rand W.M., and Thorley-Lawson D.A. EBV and systemic lupus erythematosus: a new perspective. (see comment). Journal of Immunology 174 (2005) 6599-6607
29. Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., Raab-Traub N., Delecluse H.J., and Kenney S.C. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. Journal of the National Cancer Institute 96 (2004) 1691-1702
30. Ropper A.H. Selective treatment of multiple sclerosis. (comment). New England Journal of Medicine 354 (2006) 965-967
31. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. (see comment). New England Journal of Medicine 354 (2006) 924-933
32. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.R., Lynn F., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. (see comment). New England Journal of Medicine 354 (2006) 911-923
33. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (see comment). New England Journal of Medicine 354 (2006) 899-910
34. Leigh I.M., Buchanan J.A., Harwood C.A., Cerio R., and Storey A. Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. Journal of Acquired Immune Deficiency Syndromes: JAIDS 21 Suppl. 1 (1999) S49-S57
35. Meyer T., Arndt R., Nindl I., Ulrich C., Christophers E., and Stockfleth E. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transplant International 16 (2003) 146-153
36. Ozsaran A.A., Ates T., Dikmen Y., Zeytinoglu A., Terek C., Erhan Y., Ozacar T., and Bilgic A. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. European Journal of Gynaecological Oncology 20 (1999) 127-130
37. Tam L.S., Chan A.Y., Chan P.K., Chang A.R., and Li E.K. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis and Rheumatism 50 (2004) 3619-3625
38. Schattner A., Friedman J., and Bentwich Z. Opportunistic infection due to unexplained CD4+ lymphocytopenia and associated Sjogren's syndrome. Rheumatology 43 (2004) 111-112
39. Prekates A., Kyprianou T., Paniara O., and Roussos C. Pneumocystis carinii pneumonia in a HIV-seronegative patient with untreated rheumatoid arthritis and CD4+ T-lymphocytopenia. European Respiratory Journal 10 (1997) 1184-1186
40. Gluck T., Kiefmann B., Grohmann M., Falk W., Straub R.H., and Scholmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. Journal of Rheumatology 32 (2005) 1473-1480
41. Issacs J.D., Greer S., Sharma S., Symmons D., Smith M., Johnston J., Waldmann H., Hale G., and Hazleman B.L. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. (see comment). Arthritis and Rheumatism 44 (2001) 1998-2008
42. Kang I., Hong M.S., Nolasco H., Park S.H., Dan J.M., Choi J.Y., and Craft J. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. Journal of Immunology 173 (2004) 673-681
43. Amyes E., McMichael A.J., and Callan M.F. Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. Journal of Immunology 175 (2005) 5765-5773
44. Kang I., Quan T., Nolasco H., Park S.H., Hong M.S., Crouch J., Pamer E.G., Howe J.G., and Craft J. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. Journal of Immunology 172 (2004) 1287-1294
45. Zeevi A., Britz J.A., Bentlejewski C.A., Guaspari D., Tong W., Bond G., Murase N., Harris C., Zak M., Martin D., et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transplant Immunology 15 (2005) 17-24
46. Mazurek G.H., Villarino M.E., and Cdc. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Recommendations and Reports 52 (2003) 15-18
47. Ravn P., Munk M.E., Andersen A.B., Lundgren B., Nielsen L.N., Lillebaek T., Soerensen I.J., Andersen P., and Weldingh K. Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scandinavian Journal of Infectious Diseases 36 (2004) 499-501
48. Vigna-Perez M., Abud-Mendoza C., Portillo-Salazar H., Alvarado-Sanchez B., Cuevas-Orta E., Moreno-Valdes R., Baranda L., Paredes-Saharopulos O., and Gonzalez-Amaro R. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clinical and Experimental Immunology 141 (2005) 372-380
49. Sester U., Gartner B.C., Wilkens H., Schwaab B., Wossner R., Kindermann I., Girndt M., Meyerhans A., Mueller-Lantzsch N., Schafers H.J., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. American Journal of Transplantation 5 (2005) 1483-1489
50. Breinig T., Sester M., Sester U., and Meyerhans A. Antigen-specific T cell responses: determination of their frequencies, homing properties, and effector functions in human whole blood. Methods (Duluth) 38 (2006) 77-83
51. Divekar A.A., Zaiss D.M., Lee F.E., Liu D., Topham D.J., Sijts A.J., and Mosmann T.R. Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. Journal of Immunology 176 (2006) 1465-1473
52. Katsiari C.G., and Tsokos G.C. Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmunity Reviews 5 (2006) 118-121
53. Katsiari C.G., Kyttaris V.C., Juang Y.T., and Tsokos G.C. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. Journal of Clinical Investigation 115 (2005) 3193-3204
54. Tenbrock K., Kyttaris V.C., Ahlmann M., Ehrchen J.M., Tolnay M., Melkonyan H., Mawrin C., Roth J., Sorg C., Juang Y.T., et al. The cyclic AMP response element modulator regulates transcription of the TCR zeta-chain. Journal of Immunology 175 (2005) 5975-5980
55. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. New England Journal of Medicine 353 (2005) 1711-1723
56. Chan E.S., and Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Research 4 (2002) 266-273
57. Rutz M., Metzger J., Gellert T., Luppa P., Lipford G.B., Wagner H., and Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. European Journal of Immunology 34 (2004) 2541-2550
58. Kellam P., and Weiss R.A. Infectogenomics: insights from the host genome into infectious diseases. Cell 124 (2006) 695-697
59. Arcaroli J., Fessler M.B., and Abraham E. Genetic polymorphisms and sepsis. Shock 24 (2005) 300-312
60. Nakada T.A., Hirasawa H., Oda S., Shiga H., Matsuda K., Nakamura M., Watanabe E., Abe R., Hatano M., and Tokuhisa T. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. Journal of Surgical Research 129 (2005) 322-328
61. Dahmer M.K., Randolph A., Vitali S., and Quasney M.W. Genetic polymorphisms in sepsis. Pediatric Critical Care Medicine 6 (2005) S61-S73
62. Jonsen A., Bengtsson A.A., Sturfelt G., and Truedsson L. Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Research and Therapy 6 (2004) R557-R562
63. Nath S.K., Kilpatrick J., and Harley J.B. Genetics of human systemic lupus erythematosus: the emerging picture. Current Opinion in Immunology 16 (2004) 794-800
64. Ocama P., Opio C.K., and Lee W.M. Hepatitis B virus infection: current status. American Journal of Medicine 118 (2005) 1413
65. Kroon F.P., van Dissel J.T., Labadie J., van Loon A.M., and van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clinical Infectious Diseases 21 (1995) 1197-1203
66. Nelson K.E., Clements M.L., Miotti P., Cohn S., and Polk B.F. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Annals of Internal Medicine 109 (1988) 383-388
67. Davis J.P. Experience with hepatitis A and B vaccines. American Journal of Medicine 118 Suppl. 10A (2005) 7S-15S
68. Kemper C.A., Haubrich R., Frank I., Dubin G., Buscarino C., McCutchan J.A., Deresinski S.C., and California Collaborative Treatment G. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. Journal of Infectious Diseases 187 (2003) 1327-1331
69. Fogelman I., Davey V., Ochs H.D., Elashoff M., Feinberg M.B., Mican J., Siegel J.P., Sneller M., and Lane H.C. Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. Journal of Infectious Diseases 182 (2000) 435-441